GRAMD1B and infection: Overall, our results demonstrate that our newly developed red luciferase-expressing A. fumigatus strains are suitable for drug treatment efficacy studies for IPA, not only in susceptible infections but also in triazole-resistant scenarios, as implied by the observed therapeutic failure after posaconazole treatment in triazole-resistant infected mice and the beneficial effects of L-AmB in all infected mice groups, enabling the tracking of fungal burden (BLI) as early as from the first day of infection.